Physician profile
Stanley Weiner
NPI 1811933211
$1,321.98
in general payments reported to CMS, 2019-2025
18 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $24.17 · 2021: $16.67 · 2022: $221 · 2023: $120 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $252.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $220.60 | 2022 | |
| Abbott Laboratories | $132.00 | 2025 | Aveir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.96 | 2019 | |
| Pfizer INC. | $124.27 | 2019 | |
| Boston Scientific Corporation | $120.25 | 2023 | |
| Astellas Pharma US INC | $111.36 | 2019 | |
| Merck Sharp & Dohme LLC | $66.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $65.30 | 2019 | |
| Metuchen Pharmaceuticals | $56.60 | 2019 | |
| Allergan, INC. | $50.48 | 2019-2020 | |
| Amarin Pharma, INC. | $49.62 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $46.59 | 2019 | |
| Amgen INC. | $38.26 | 2019 | |
| Lilly USA, LLC | $34.04 | 2019 | |
| Glaxosmithkline, LLC. | $23.08 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $21.95 | 2019 | |
| Hikma Pharmaceuticals USA | $17.98 | 2019 | |
| Abbvie INC. | $16.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.